AdrenalImprove detection and treatment of endocrine hypertension

Use the resources from the recently published Scientific Statement on screening for endocrine hypertension to improve early detection of curable forms of hypertension. And apply the new clinical guideline on the management of primary aldosteronism, which calls primary aldosteronism a major public health challenge.

Endocrine Society Issues Scientific Statement to Improve Detection of Curable Forms of Hypertension
April 6, 2017 | A new Scientific Statement issued by the Endocrine Society advises healthcare providers on ways to spot hormonal causes of high blood pressure that can be cured…

Stressed Out: New Treatment Guidelines for Primary Aldosteronism
October 2016 | A new Endocrine Society Clinical Practice Guideline calls primary aldosteronism a major public health challenge. Research shows that an excessive level of aldosterone, far from…

John W. Funder Awarded Fondation IPSEN Endocrine Regulations Prize
September 2016 | Endocrine Society member John W. Funder, MD, PhD, of Prince Henry’s Institute in Victoria, Australia, today was awarded the Fondation PSEN Endocrine Regulations Prize for…

Explore highlights of current education across the Endocrine Society.

Primary Hyperaldosteronism
ENDO Session | No credit available
William F Young, Jr., MD, MSc
Review email consults in a computer-based CPC to learn practical approaches to diagnosing and treating hyperaldosteronism.

Clinical Management of Adrenocortical Carcinoma
ENDO Session | No credit available
Martin Fassnacht, MD
Review the options, as well as the pros and cons for each step in surgical and medical management of ACC.

Management of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
ENDO Session | No credit available
Stefan Bornstein, MD, PhD; Wiebke Arlt, MD, DSc; Constantine A. Stratakis, MD; Deborah P. Merke, MS, MD; Eystein Sverre Husebye, MD, PhD; David J Torpy, MBBS, PhD; Andrew C. Don-Wauchope, MD; and Paul M. Stewart, MD
Hear the recommendations and controversies directly from the guideline committee with case examples and rationales for the newest guideline.

Endocrine Facts & Figures: Adrenal
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on adrenal insufficiency and Cushing syndrome with current citations and expert insights.

Explore highlights of current publications across the Endocrine Society journals. Visit for more.

Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series
JCEM | July 30, 2017
Sara G Creemers, Esther Korpershoek, Peggy N Atmodimedjo, Winand N M Dinjens, Peter M van Koetsveld, Richard A Feelders, and Leo J Hofland
We report the presence of circulating cell-free tumor DNA in the plasma of a patient with metastatic ACC after previous mutation identification in the primary tumor.

Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals
JES | May 12, 2017
Kei Omata, Sharath K. Anand, Daniel H. Hovelson, Chia-Jen Liu, Yuto Yamazaki, Yasuhiro Nakamura, Sadayoshi Ito, Fumitoshi Satoh, Hironobu Sasano, William E. Rainey, and Scott A. Tomlins
Primary aldosteronism (PA) accounts for ∼4% to 10% of all hypertensive patients and is one of the few curable forms of hypertension. Increased aldosterone levels, in addition to hypertension, have been reported to…

Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease
JCEM | May 12, 2017
Fabio R Faucz, Amit Tirosh, Christina Tatsi, Annabel Berthon, Laura C Hernández-Ramírez, Nikolaos Settas, Anna Angelousi, Ricardo Correa, Georgios Z Papadakis, Prashant Chittiboina, Martha Quezado, Nathan Pankratz, John Lane, Aggeliki Dimopoulos, James L Mills, Maya Lodish, and Constantine A Stratakis
As in adults, adrenocorticotropic hormone (ACTH)-producing pituitary adenomas are the most common cause of endogenous hypercortisolemia in children, especially after the age of 7 years…

Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
JES | April 28, 2017
Anne-Cecile Paepegaey, Coralie Lheure, Carole Ratour, Gaëlle Lethielleux, Jerome Clerc, Jerome Bertherat, Nora Kramkimel, and Lionel Groussin
Checkpoint inhibitors have significantly improved the prognosis of patients with advanced melanoma. These cancer immunotherapy drugs have specific endocrine autoimmune toxicity…

Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Endocrine Reviews | April 5, 2017
William F. Young, Jr., David A. Calhoun, Jacques W.M. Lenders, Michael Stowasser, Stephen C. Textor
Hypertension affects 28.6% of adults in United States. In most, hypertension is primary (essential or idiopathic), but a subgroup of approximately 15% has secondary hypertension…

Glucose Metabolism Abnormalities in Cushing's Syndrome: From Molecular Basis to Clinical Management
Endocrine Reviews | March 20, 2017
Carla Scaroni, Marialuisa Zilio, Michelangelo Foti, and Marco Boscaro
An impaired glucose metabolism, which often leads to the onset of diabetes mellitus (DM), is a common complication of chronic exposure…

A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy
Endocrinology | February 14, 2017
Meredith D. Hartley, Lisa L. Kirkemo, Tapasree Banerji, and Thomas S. Scanlan
X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder affecting 1 in 17,000 people worldwide that causes adrenal gland dysfunction and loss of…

Primary Aldosteronism as a Risk Factor for Vertebral Fracture
JCEM | February 09, 2017
Masakazu Notsu, Mika Yamauchi, Masahiro Yamamoto, Kiyoko Nawata,and Toshitsugu Sugimoto
Some observational studies have revealed an association between excessive aldosterone levels and reduced bone mineral density…

A SDHC Founder Mutation Causes Paragangliomas (PGLs) in the French Canadians: New Insights on the SDHC-Related PGL
JCEM | October 4, 2016
Isabelle Bourdeau, Solange Grunenwald, Nelly Burnichon, Emmanuel Khalifa, Nadine Dumas, Marie-Claire Binet, Serge Nolet and Anne-Paule Gimenez-Roqueplo
More than 40% of patients with paragangliomas (PGLs) harbor a germline mutation of the known PGL susceptibility genes, mainly in the SDHB or SDHD genes…

A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans
JCEM | September 28, 2016
Agnieszka Pazderska, Bergithe E. Oftedal, Catherine M. Napier, Holly F. Ainsworth, Eystein S. Husebye, Heather J. Cordell, Simon H. S. Pearce and Anna L. Mitchell
Autoimmune Addison's disease (AAD) is a rare but highly heritable condition. The BACH2 protein plays a crucial role in T lymphocyte maturation, and allelic variation…

Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency
JCEM | September 13, 2016
Paul M. Stewart, Beverly M. K. Biller, Claudio Marelli, Candace Gunnarsson, Michael P. Ryan and Gudmundur Johannsson
Patients with adrenal insufficiency (AI) (primary AI [PAI], secondary AI due to a pituitary disorder [PIT] and congenital adrenal hyperplasia [CAH]) have reduced life expectancy…

For a complete list of Endocrine Society guidelines, visit

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment
JCEM | March 2, 2016
John W. Funder, Robert M. Carey, Franco Mantero, M. Hassan Murad, Martin Reincke, Hirotaka Shibata, Michael Stowasser, and William F. Young Jr.
For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio …

Diagnosis and Treatment of Primary Adrenal Insufficiency
JCEM | February 01, 2016
Stefan R. Bornsteinchair, Bruno Allolio, Wiebke Arlt, Andreas Barthel, Andrew Don-Wauchope, Gary D. Hammer, Eystein S. Husebye, Deborah P. Merke, M. Hassan Murad, Constantine A. Stratakis, and David J. Torpy
We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic…

Treatment of Cushing's Syndrome
JCEM | July 29, 2015
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…

Diagnosis and Treatment of Pheochromocytoma and Paraganglioma
JCEM | June 3, 2014
Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, and William F. Young Jr
The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical factors…

Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency
JCEM | April 30, 2011
Phyllis W. Speiser, Ricardo Azziz, Laurence S. Baskin, Lucia Ghizzoni, Terry W. Hensle, Deborah P. Merke, Heino F. L. Meyer-Bahlburg, Walter L. Miller, Victor M. Montori, Sharon E. Oberfield, Martin Ritzen, and Perrin C. White
We recommend universal newborn screening for severe steroid 21-hydroxylase deficiency followed by confirmatory tests. We recommend that prenatal treatment of CAH continue to be regarded as…

The Diagnosis of Cushing's Syndrome
JCEM | January 14, 2009
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…

For additional meetings, visit the Endocrine Society's Worldwide Endocrinology Calendar at

ENDO 2018
Dates: March 17–20, 2018
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.